In this video, InMed Pharmaceuticals’ CEO Eric A. Adams speaks about the company’s therapeutic development of cannabinol (CBN), a rare cannabinoid showing potential to treat serious diseases with high unmet needs. InMed is the first company to advance CBN into clinical trials for therapeutic development. Mr. Adams also provides an update on the company’s programs in epidermolysis bullosa (EB) and glaucoma and its biosynthesis platform.
![](https://www.inmedpharma.com/wp-content/uploads/2024/08/InMed-Native-Article_Neuron-close-up-768x432.png)
Article in Fierce Biotech: The Evolving Alzheimer’s Disease Landscape
There have been major advances in Alzheimer’s disease research and development in the past two years alone. What are those breakthroughs and what’s in development